Inclusion criteria:
1. Adult patients with newly diagnosed HER2-positive breast cancer who have not previously received any taxane- and trastuzumab-containing chemotherapy regimen.
2. Patients scheduled to receive a taxane-based chemotherapy regimen consisting of either paclitaxel 80 mg/m² IV weekly or docetaxel 75–100 mg/m² IV every three weeks, in combination with trastuzumab (typically 6 mg/kg IV every three weeks).
3. Patients must have a baseline left ventricular ejection fraction (LVEF) of ≥ 50% at study enrollment
4. Patients must have no history of cardiovascular diseases, including heart failure, angina, or hypertension.
5. Patients must provide informed consent to participate in the study and agree to comply with the study protocol, including a minimum follow-up period of three months.
Exclusion criteria:
1. Patients with a systolic blood pressure of less than 100 mmHg.
2. Patients with contraindications to angiotensin-converting enzyme inhibitors (ACEIs), angiotensin II receptor blockers (ARBs), or neprilysin inhibitors.
3. Patients who develop potential adverse effects or hypersensitivity reactions to sacubitril/valsartan or enalapril during the course of treatment.
4. Patients with renal impairment, defined as an estimated glomerular filtration rate (eGFR) of less than 45 mL/min/1.73 m².
5. Patients with a serum potassium level greater than 5 mmol/L.
6. Patients who have experienced adverse effects, such as angioedema or cough, following the use of enalapril or other ACEIs.
7. Patients who develop another serious medical condition during the intervention period that necessitates treatment with medications affecting the cardiovascular system.